Author:
Jaffari Hamza Abbas,Mazhar Sumaira
Abstract
Hepatocellular carcinoma (HCC) is a standout amongst the most widely recognized cancers around the world, and just as the alcoholic liver disease it is also progressed by extreme viral hepatitis B or C. At the early stage of the disease, numerous patients are asymptomatic consequently late diagnosis of HCC occurs resulting in expensive surgical resection or transplantation. On the basis of the alpha fetoprotein (AFP) estimation, combined with the ultrasound and other sensitive imaging techniques used, the non-invasive detection systems are available. For early disease diagnosis and its use in the effective treatment of HCC patients, the identification of HCC biomarkers has provided a breakthrough utilizing the molecular genetics and proteomics. In the current article, most recent reports on the protein biomarkers of HBV or HCV-related HCC and their co-evolutionary association with liver cancer are reviewed.
Publisher
CrossLinks International Publishers
Reference38 articles.
1. 1. D.M. Parkin, F. Bray, J. Ferlay and P. Pisani, P, "Global cancer statistics, 2002" CA: A Cancer Journal of Clinicians, vol. 55, no. 2, pp. 74-108, 2005.
2. 2. H.B. El-Serag, Hepatocellular carcinoma. New England Journal Medicine, vol. 365, no. 12, pp. 1118-1127, 2011.
3. 3. F. Zoulim and S. Locarnini, "Management of treatment failure in chronic hepatitis B" Journal of Hepatolology, vol. 56, pp. 112-122, 2012.
4. 4. V.F.N. Kumar and A. Abbas, Pathologic Basis of Disease, 7th ed. Philadelphia, Pa.: Elsevier Saunders, 2003.
5. 5. G.J. Mizejewski, "Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants" Experimental Biology and Medicine (Maywood), vol. 226, no. 5, pp. 377-408, 2001.